Medtide launches IPO to bulk up its weight-loss business
The pharmaceutical services firm wants to expand production of peptides used in anti-obesity drugs, but it faces fierce competition and other business risks Key Takeaways: The global market for developing…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
- RNA drug developer Ribo Life targets fresh funding channel
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
WuXi group wrestles with uncertainty over pharma tariffs
2268.HK
